11
Nov
Combination oral letermovir, VGC/GCV, and CMV-HIG achieved stable CMV viremia clearance (Di Cristanziano et al., 2021). treatment-related mortality or serious adverse events were associated. Conclusion: CMV-HIG is an effective treatment option in SCT patients that is as safe as antivirals alone. Preemptive BMN673 CMV-HIG with antivirals may provide the added advantage of reduced time to viremia clearance without adding renal injury. Larger, prospective studies are needed to evaluate CMV-HIG's impact on time to viremia clearance and the effectiveness of preemptive CMV-HIG use with antivirals. Cytomegalovirus (CMV) is a major cause of morbidity and mortality in immunocompromised patients following stem cell…